Cannabis Use Is an Independent Predictor for Acute Myocardial Infarction Related Hospitalization in Younger Population



      This study aimed to evaluate the risk of various substances in young acute myocardial infarction (AMI) inpatients and analyze patient demographics and hospital outcomes for significant substance use risk factors.


      We conducted a retrospective analysis of the Nationwide Inpatient Sample data (2010–2014). Patients (aged 15–22 years) with a primary diagnosis for AMI (N = 1,694) were compared with non-AMI (N = 9,465,255) inpatients for odds ratio (OR) of substance use by logistic regression model, adjusted for demographics, medical risk factors, and comorbid substance use.


      Tobacco (28.4%) and cannabis (14.9%) use were most prevalent in AMI inpatients. Cocaine (OR = 3.9), amphetamine (OR = 2.3), and cannabis (OR = 1.3) users were at higher risk of AMI hospitalizations. Higher proportion of cannabis users (14.7%) had major severity of illness at admission and higher mean total charge ($53,608) compared with that seen in cocaine and amphetamine users. Angioplasty was used more in cannabis users (19.4%) than others. The in-hospital mortalities were 2.7% and 2% in overall AMI cohort and cannabis users, respectively, and none in cocaine and amphetamine users.


      Our study demonstrates a higher prevalence and significant odds of AMI inpatients with cannabis use, along with the potential cost burdens because of severe morbidity and higher use of treatment modalities. Physicians need to familiarize themselves with rising use of cannabis and other substances in adolescent and younger population and the typical presentations of cannabis-induced myocardial infarction.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Adolescent Health
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ghuran A.
        • Nolan J.
        The cardiac complications of recreational drug use.
        West J Med. 2000; 173: 412-415
        • Johnston L.D.
        • Miech R.A.
        • O'Malley P.M.
        • et al.
        Monitoring the future national survey results on drug use: 1975-2017: Overview, key findings on adolescent drug use.
        Institute for Social Research, The University of Michigan, Ann Arbor, MI2018
        • Cerda M.
        • Sarvet A.L.
        • Wall M.
        • et al.
        Medical marijuana laws and adolescent use of marijuana and other substances: Alcohol, cigarettes, prescription drugs, and other illicit drugs.
        Drug Alcohol Depend. 2018; 183: 62-68
        • Carpenter C.S.
        • McClellan C.B.
        • Rees D.I.
        Economic conditions, illicit drug use, and substance use disorders in the United States.
        J Health Econ. 2017; 52: 63-73
        • Mouhaffel A.H.
        • Madu E.C.
        • Satmary W.A.
        • Fraker Jr., T.D.
        Cardiovascular complications of cocaine.
        Chest. 1995; 107: 1426-1434
        • Packe G.E.
        • Garton M.J.
        • Jennings K.
        Acute myocardial infarction caused by intravenous amphetamine abuse.
        Br Heart J. 1990; 64: 23-24
        • Smith H.J.
        • Roche A.H.
        • Jausch M.F.
        • Herdson P.B.
        Cardiomyopathy associated with amphetamine administration.
        Am Heart J. 1976; 91: 792-797
        • Simpson L.L.
        Blood pressure and heart rate responses evoked by d- and l-amphetamine in the pithed rat preparation.
        J Pharmacol Exp Ther. 1975; 193: 149-159
        • Taeuber K.
        • Zapf R.
        • Rupp W.
        • Badian M.
        Pharmacodynamic comparison of the acute effects of nomifensine, amphetamine and placebo in healthy volunteers.
        Int J Clin Pharmacol Biopharm. 1979; 17: 32-37
        • Schwartz B.G.
        • Rezkalla S.
        • Kloner R.A.
        Cardiovascular effects of cocaine.
        Circulation. 2010; 122: 2558-2569
        • Compton W.M.
        • Grant B.F.
        • Colliver J.D.
        • et al.
        Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002.
        JAMA. 2004; 291: 2114-2121
        • Lindsay A.C.
        • Foale R.A.
        • Warren O.
        • Henry J.A.
        Cannabis as a precipitant of cardiovascular emergencies.
        Int J Cardiol. 2005; 104: 230-232
        • Culic V.
        Acute risk factors for myocardial infarction.
        Int J Cardiol. 2007; 117: 260-269
        • Goyal H.
        • Awad H.H.
        • Ghali J.K.
        Role of cannabis in cardiovascular disorders.
        J Thorac Dis. 2017; 9: 2079-2092
        • Singh A.
        • Saluja S.
        • Kumar A.
        • et al.
        Cardiovascular complications of marijuana and related substances: A review.
        Cardiol Ther. 2018; 7: 45-59
        • Zendulka O.
        • Dovrtelova G.
        • Noskova K.
        • et al.
        Cannabinoids and cytochrome P450 interactions.
        Curr Drug Metab. 2016; 17: 206-226
        • Osula S.
        • Bell G.M.
        • Hornung R.S.
        Acute myocardial infarction in young adults: Causes and management.
        Postgrad Med J. 2002; 78: 27-30
        • Zhu H.
        • Wu L.T.
        Trends and correlates of cannabis-involved emergency department visits: 2004 to 2011.
        J Addict Med. 2016; 10: 429-436
        • Patel R.S.
        • Katta S.R.
        • Patel R.
        • et al.
        Cannabis use disorder in young adults with acute myocardial infarction: Trend inpatient study from 2010 to 2014 in the United States.
        Cureus. 2018; 10: e3241
      1. HCUP NIS database documentation.
        (Available at:) (Accessed June 9, 2018)
      2. NIS description of data elements. Healthcare Cost and Utilization Project (HCUP).
        (Available at:)
        Date: 2017
        Date accessed: June 9, 2018
        • Kiani F.
        • Hesabi N.
        • Arbabisarjou A.
        Assessment of risk factors in patients with myocardial infarction.
        Glob J Health Sci. 2015; 8: 255-262
        • Anand S.S.
        • Islam S.
        • Rosengren A.
        • et al.
        Risk factors for myocardial infarction in women and men: Insights from the INTERHEART study.
        Eur Heart J. 2008; 29: 932-940
        • Flores E.D.
        • Lange R.A.
        • Cigarroa R.G.
        • Hillis L.D.
        Effect of cocaine on coronary artery dimensions in atherosclerotic coronary artery disease: Enhanced vasoconstriction at sites of significant stenoses.
        J Am Coll Cardiol. 1990; 16: 74-79
        • Sichilima T.
        • Rieder M.J.
        Adderall and cardiovascular risk: A therapeutic dilemma.
        Paediatr Child Health. 2009; 14: 193-195
        • Westover A.N.
        • McBride S.
        • Haley R.W.
        Stroke in young adults who abuse amphetamines or cocaine: A population-based study of hospitalized patients.
        Arch Gen Psychiatry. 2007; 64: 495-502
        • Virmani R.
        • Robinowitz M.
        • Smialek J.E.
        • Smyth D.F.
        Cardiovascular effects of cocaine: An autopsy study of 40 patients.
        Am Heart J. 1988; 115: 1068-1076
        • Brody S.L.
        • Slovis C.M.
        • Wrenn K.D.
        Cocaine-related medical problems: Consecutive series of 233 patients.
        Am J Med. 1990; 88: 325-331
        • Baumann B.M.
        • Perrone J.
        • Hornig S.E.
        • et al.
        Randomized, double-blind, placebo-controlled trial of diazepam, nitroglycerin, or both for treatment of patients with potential cocaine-associated acute coronary syndromes.
        Acad Emerg Med. 2000; 7: 878-885
        • Carrillo X.
        • Curos A.
        • Muga R.
        • et al.
        Acute coronary syndrome and cocaine use: 8-year prevalence and inhospital outcomes.
        Eur Heart J. 2011; 32: 1244-1250
        • Nawrot T.S.
        • Perez L.
        • Kunzli N.
        • et al.
        Public health importance of triggers of myocardial infarction: A comparative risk assessment.
        Lancet. 2011; 377: 732-740
        • Jouanjus E.
        • Raymond V.
        • Lapeyre-Mestre M.
        • Wolff V.
        What is the current knowledge about the cardiovascular risk for users of cannabis-based products? A systematic review.
        Curr Atheroscler Rep. 2017; 19: 26
        • Dines A.M.
        • Wood D.M.
        • Galicia M.
        • et al.
        Presentations to the emergency department following cannabis use--a multi-centre case series from ten European countries.
        J Med Toxicol. 2015; 11: 415-421
        • Mittleman M.A.
        • Lewis R.A.
        • Maclure M.
        • et al.
        Triggering myocardial infarction by marijuana.
        Circulation. 2001; 103: 2805-2809
        • Williams J.C.
        • Klein T.W.
        • Goldberger B.A.
        • et al.
        Delta(9)-Tetrahydrocannabinol (THC) enhances lipopolysaccharide-stimulated tissue factor in human monocytes and monocyte-derived microvesicles.
        J Inflamm (Lond). 2015; 12: 39
        • Berger E.
        Legal marijuana and pediatric exposure pot edibles implicated in spike in child emergency department visits.
        Ann Emerg Med. 2014; 64: A19-A21
        • Faber J.
        • Fonseca L.M.
        How sample size influences research outcomes.
        Dental Press J Orthod. 2014; 19: 27-29
        • Mentz R.J.
        • Newby L.K.
        • Neely B.
        • et al.
        Assessment of administrative data to identify acute myocardial infarction in electronic health records.
        J Am Coll Cardiol. 2016; 67: 2441-2442
        • Rubbo B.
        • Fitzpatrick N.K.
        • Denaxas S.
        • et al.
        Use of electronic health records to ascertain, validate and phenotype acute myocardial infarction: A systematic review and recommendations.
        Int J Cardiol. 2015; 187: 705-711